PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
8935.00 - 9125.00
6347.00 - 10045.00
380.0K / 335.9K (Avg.)
23.15 | 391.09
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
5.19%
Positive revenue growth while 3391.T is negative. John Neff might see a notable competitive edge here.
1.77%
Positive gross profit growth while 3391.T is negative. John Neff would see a clear operational edge over the competitor.
-21.19%
Negative EBIT growth while 3391.T is at 72.29%. Joel Greenblatt would demand a turnaround plan focusing on core profitability.
-22.23%
Negative operating income growth while 3391.T is at 12.14%. Joel Greenblatt would press for urgent turnaround measures.
9.10%
Net income growth under 50% of 3391.T's 26.24%. Michael Burry would suspect the firm is falling well behind a key competitor.
9.10%
EPS growth under 50% of 3391.T's 26.22%. Michael Burry would suspect deeper structural issues or share dilution limiting per-share gains.
9.10%
Diluted EPS growth under 50% of 3391.T's 26.03%. Michael Burry would worry about an eroding competitive position or excessive dilution.
-0.00%
Both firms reduce share counts. Martin Whitman would compare buyback intensity relative to free cash flow generation.
-0.00%
Reduced diluted shares while 3391.T is at 0.16%. Joel Greenblatt would see a relative advantage if the competitor is diluting more.
15.38%
Dividend growth of 15.38% while 3391.T is flat. Bruce Berkowitz would see if this can become a bigger advantage long term.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
145.37%
Similar 10Y revenue/share CAGR to 3391.T's 139.60%. Walter Schloss might see both firms benefiting from the same long-term demand.
35.19%
5Y revenue/share CAGR 1.25-1.5x 3391.T's 25.74%. Bruce Berkowitz would verify if cost efficiency or pricing power supports this advantage.
31.75%
3Y revenue/share CAGR 1.25-1.5x 3391.T's 21.47%. Bruce Berkowitz might see better product or regional expansions than the competitor.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
144.02%
Net income/share CAGR at 50-75% of 3391.T's 260.20%. Martin Whitman might question if the firm’s product or cost base lags behind.
19.91%
Below 50% of 3391.T's 140.34%. Michael Burry would worry about a substantial lag vs. the competitor’s profit ramp-up.
28.78%
Below 50% of 3391.T's 346.10%. Michael Burry suspects a steep short-term disadvantage in bottom-line expansion.
295.46%
10Y equity/share CAGR above 1.5x 3391.T's 111.08%. David Dodd would confirm if consistent earnings retention or fewer write-downs drive this advantage.
76.61%
5Y equity/share CAGR above 1.5x 3391.T's 20.98%. David Dodd might see stronger earnings retention or fewer asset impairments fueling growth.
35.05%
3Y equity/share CAGR above 1.5x 3391.T's 9.60%. David Dodd verifies the company’s short-term capital management far exceeds the competitor’s pace.
361.54%
Dividend/share CAGR of 361.54% while 3391.T is zero. Bruce Berkowitz sees a slight advantage in stepping up payouts steadily.
150.00%
Dividend/share CAGR of 150.00% while 3391.T is zero. Bruce Berkowitz sees a minor advantage in stepping up distributions, even modestly.
87.50%
3Y dividend/share CAGR of 87.50% while 3391.T is zero. Bruce Berkowitz sees a minor positive difference that could attract dividend-focused investors.
1721.43%
AR growth well above 3391.T's 30.38%. Michael Burry fears inflated revenue or higher default risk in the near future.
4.84%
Inventory growth well above 3391.T's 2.69%. Michael Burry suspects overshooting production or weaker sell-through vs. the competitor.
10.68%
Asset growth above 1.5x 3391.T's 4.55%. David Dodd checks if M&A or new capacity expansions are value-accretive vs. competitor's approach.
3.47%
BV/share growth above 1.5x 3391.T's 1.68%. David Dodd confirms if consistent profit retention or fewer write-downs yield faster equity creation.
75.11%
We have some new debt while 3391.T reduces theirs. John Neff sees the competitor as more cautious unless our expansions pay off strongly.
No Data
No Data available this quarter, please select a different quarter.
8.24%
We expand SG&A while 3391.T cuts. John Neff might see the competitor as more cost-optimized unless we expect big payoffs from the overhead growth.